Key Structural and Operational Considerations for Biosimilar Adoption

Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

Now Viewing

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

Video content above is prompted by the following:

• When health care systems move to biosimilar adoption, what are the key structural and operational considerations that go into this transition?

Related Videos

Related Content

Advertisement

February 19th 2025

What Recent Evidence Is Telling Us About Alcohol and Cancer

Produced by Mary Caffrey

Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 18th 2025

Sugammadex Safe, Effective Post Surgery in Myasthenia Gravis

Maggie L. Shaw

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular blockade from rocuronium bromide or vecuronium bromide.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 18th 2025

Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC

Mary Caffrey

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).

February 16th 2025

“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”

Regina Barragan-Carrillo, MD Interview by Mary Caffrey

Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.

Related Content

Advertisement

February 19th 2025

What Recent Evidence Is Telling Us About Alcohol and Cancer

Produced by Mary Caffrey

Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 18th 2025

Sugammadex Safe, Effective Post Surgery in Myasthenia Gravis

Maggie L. Shaw

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular blockade from rocuronium bromide or vecuronium bromide.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 18th 2025

Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC

Mary Caffrey

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).

February 16th 2025

“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”

Regina Barragan-Carrillo, MD Interview by Mary Caffrey

Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.